MaxCyte and KSQ Therapeutics announce development & commercialization agreement to enable the advancement of KSQ’s Adoptive Cell Therapy Programs
MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new
LEARN MORE